ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $61.14M rose 24066.0% year over year, ahead of the +17210.3% change in trailing-twelve-month financing cash flow. Sequentially, it rose 3976.0% from the prior quarter. Over 3 fiscal years it compounded at +114.1% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24066.0% holds above the trailing-twelve-month pace of +17210.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 247.66M USD
- Year-over-year change
- +95.7%
- 4-year CAGR
- +49.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 247.66M | +95.7% |
| FY2024 | 2024-12-31 | 126.55M | +47.7% |
| FY2023 | 2023-12-31 | 85.66M | +239.6% |
| FY2022 | 2022-12-31 | 25.23M | -48.7% |
| FY2021 | 2021-12-31 | 49.13M | — |
Financing Cash Flow vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 financing cash flow of $306.39M is the 2nd largest of the 11 companies compared; the peer median is $172.72M.
- Its year-over-year change of +17210.3% is the highest of 11, against a peer median of +84.8%.
- Over three fiscal years its annual growth of +114.1% compares with a peer median of +93.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $476.48M | +84.5% | — | — | |
| LTM Mar 2026 | $306.39M | +17210.3% | +114.1% | — | |
| LTM Mar 2026 | $251.18M | +3158.7% | +6.2% | — | |
| LTM Mar 2026 | $226.9M | +360.2% | — | — | |
| LTM Mar 2026 | $224.57M | +85.0% | +72.0% | 452.9% | |
| LTM Jun 2026 | $179.14M | -6.5% | +434.4% | 105.4% | |
| LTM Mar 2026 | $166.3M | +4048.1% | +134.0% | — | |
| LTM Mar 2026 | $69.59M | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $20.66M | -94.1% | -57.0% | 9.5% | |
| LTM Mar 2026 | $13.61M | -39.4% | +1.5% | — | |
| LTM Mar 2026 | $7.94M | -98.0% | +114.7% | 36.7% | |
| Peer median (excluding ORIC) | $172.72M | +84.8% | +93.3% | 44.3% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.85M | 14.46M | 15.23M | 20.21M | 0 |
| Change in Working Capital | 4.07M | (445K) | 4.9M | 1.97M | (5.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.93M | (1.48M) | 0 | 1.83M | (7.25M) |
| Other Working Capital | 1.14M | 1.03M | 4.9M | 143K | 1.79M |
| Other Non-Cash Items | 1.35M | (1M) | (6.15M) | (8.1M) | 20.34M |
| Operating Cash Flow | (59.54M) | (75.14M) | (85.69M) | (112.66M) | (113.37M) |
| Capital Expenditures | (939K) | (2.08M) | (849K) | (1.19M) | (712K) |
| Acquisitions (Net) | 1.38M | 2.08M | 0 | 0 | 0 |
| Purchases of Investments | (69.63M) | (238.12M) | (239.24M) | (251.92M) | (399.82M) |
| Sales of Investments | 229M | 130.95M | 196.69M | 275.25M | 252.5M |
| Other Investing Activities | (1.38M) | (2.08M) | 0 | 0 | 0 |
| Investing Cash Flow | 158.44M | (109.25M) | (43.4M) | 22.14M | (148.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 50M | 25M | 85M | 125M | 247.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (866K) | 225K | 658K | 1.55M | 0 |
| Financing Cash Flow | 49.13M | 25.23M | 85.66M | 126.55M | 247.66M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 148.03M | (159.17M) | (43.43M) | 36.02M | (13.74M) |
| Free Cash Flow | (60.48M) | (77.22M) | (86.54M) | (113.85M) | (114.08M) |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.